Epsilon HealthcareASX:EPN Net Margin % is 13.18% as of Dec. 2025. The stock has 4 warning signs investors should review. Among 956 Drug Manufacturers companies, Epsilon Healthcare ranks worse than 78.35% on this metric.
The historical rank and industry rank for Epsilon Healthcare's Net Margin % or its related term are showing as below:
ASX:EPN'
s Net Margin % Range Over the Past 10 Years
Min: -323.24 Med: -157.46 Max: -13.62
Current: -13.62
ASX:EPN's Net Margin % is ranked worse than 78.35% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs ASX:EPN: -13.62
Epsilon Healthcare (ASX:EPN) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Epsilon Healthcare Net Margin % Related Terms
Epsilon Healthcare Net Margin % Historical Data
* Premium members only.
The historical data trend for Epsilon Healthcare's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Epsilon Healthcare's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Epsilon Healthcare Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Epsilon Healthcare's Net Margin % distribution charts can be found below:
* The bar in red indicates where Epsilon Healthcare's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Epsilon Healthcare (ASX:EPN) has a Net Margin % of 13.18% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Epsilon Healthcare and its competitors. According to the industry distribution chart, Epsilon Healthcare ranks #749 out of 956 companies in the Drug Manufacturers industry, placing it in the top 78.3%.
Is Epsilon Healthcare's Net Margin % too high?
Epsilon Healthcare's current Net Margin % is 13.18%. The Drug Manufacturers industry median Net Margin % is 5.56. Epsilon Healthcare's value of 13.18% is 137.1% above this industry median. Based on the distribution chart, Epsilon Healthcare ranks #749 out of 956 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Epsilon Healthcare's Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Epsilon Healthcare ranks #749 out of 956 companies for Net Margin %. This places Epsilon Healthcare in the lower half of its industry. The industry median Net Margin % is 5.56. Epsilon Healthcare's value of 13.18% is 137.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Epsilon Healthcare's current Net Margin % of 13.18% is 137.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Epsilon Healthcare and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Epsilon Healthcare's current Net Margin % is 13.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Epsilon Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Epsilon Healthcare (ASX:EPN) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.02 — trading 26.7% below its estimated fair value. The current Net Margin % is 13.18% and 137.1% above the Drug Manufacturers industry median of 5.56. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Epsilon Healthcare (ASX:EPN), the current Net Margin % is 13.18% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Epsilon Healthcare Ltd is an Australian based, globally active healthcare organisation. It operates a diversified and vertically integrated portfolio of assets, including healthcare and clinics operation, pharmaceutical contract development and manufacturing operation & pharmacy services. The company offers end-to-end solutions across the healthcare spectrum: from product development and manufacturing to patient care. The company's three (3) main operating segments are: a. Contract Development and Manufacturing activities, b. Telehealth medical practice services; and c. Pharmacy services. The majority of revenue is derived from the Contract Development and Manufacturing activities segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EPN has been successfully added to your 